Oncolysis using herpes simplex virus type 1 Engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 2, 2010, Pages 151-158

  Price, Daniel L ^a   Lin, Shu Fu ^a,b   Han, Ziqun ^c   Simpson, Guy ^c   Coffin, Robert S ^c   Wong, Joyce ^a   Li, Sen ^a   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c Biovex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN;

ARTICLE; BIOENGINEERING; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; HEAD AND NECK CARCINOMA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HERPESVIRUS 1, HUMAN; HUMANS; LEUKEMIA VIRUS, GIBBON APE; ONCOLYTIC VIROTHERAPY; PRODRUGS;

EID: 77149156995     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.214     Document Type: Article

References (25)

1. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER cancer statistics review 1975-2004. http://seer.cancer.gov/csr/1975-2004/. Accessed January 4, 2010.
2. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952.
3. Cooper JS, Pajak TF, Forastiere AA, et al; Radiation Therapy Oncology Group 9501/ Intergroup. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350 (19):1937-1944.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-2098.
5. Numico G, Russi EG, Vitiello R, et al. Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule. Int J Radiat Oncol Biol Phys. 2006;66 (3):731-737.
6. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Support Care Cancer. 2008;16(2):171-179.
7. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):23-28.
8. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685-1690.
9. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg. 2001;233(6):819-826.
10. Derubertis BG, Stiles BM, Bhargava A, et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther. 2007;14(6):590-597.
11. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000;97(5):2208-2213.
12. Wong RJ, Chan MK, Yu Z, et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res. 2004;10(13):4509-4516.
13. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res. 2004;10(1, pt 1):251-259.
14. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther. 2001;12 (3):253-265.
15. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737-6747.
16. Malhotra S, Kim T, Zager J, et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery. 2007;141(4):520-529.
17. Guffey MB, Parker JN, Luckett WS Jr, et al. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007;14(1):45-56.
18. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res. 2006;66(9):4835-4842.
19. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003;7(6):748-754.
20. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett. 1998;167 (1):41-49.
21. Fu KK. Radiation therapy with 5-fluorouracil in head and neck cancer. Semin Radiat Oncol. 1997;7(4):274-282.
22. Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001; 12(7):811-821.
23. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A. 1994;91(17):8302-8306.
24. Grem JL. Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol. 1997;7(4):249-259.
25. Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am. 1980;13(3):515-520.